Thrombus aspiration in patients with ST-elevation myocardial infarction: results of a national registry of interventional cardiology

Hélder Pereira1,2*, Daniel Caldeira1,2,3†, Rui Campante Teles4,5, Marco Costa6, Pedro Canas da Silva7, Vasco da Gama Ribeiro8, Vítor Brandão9, Dinis Martins10, Fernando Matias11, Francisco Pereira-Machado12, José Baptista13, Pedro Farto e Abreu14, Ricardo Santos15, António Drummond16, Henrique Cyrne de Carvalho17, João Calisto18, João Carlos Silva19, João Luís Pipa20, Jorge Marques21, Paulino Sousa22, Renato Fernandes23, Rui Cruz Ferreira24, Sousa Ramos25, Eduardo Infante Oliveira2,5,7, Manuel de Sousa Almeida26 and on behalf of the investigators of Portuguese Registry on Interventional Cardiology (Registo Nacional de Cardiologia de Intervenção)

Abstract

Background: We aimed to evaluate the impact of thrombus aspiration (TA) during primary percutaneous coronary intervention (P-PCI) in ‘real-world’ settings.

Methods: We performed a retrospective study, using data from the National Registry of Interventional Cardiology (RNCI 2006–2012, Portugal) with ST-elevation myocardial infarction (STEMI) patients treated with P-PCI. The primary outcome, in-hospital mortality, was analysed through adjusted odds ratio (aOR) and 95% confidence intervals (95%CI).

Results: We assessed data for 9458 STEMI patients that undergone P-PCI (35% treated with TA). The risk of in-hospital mortality with TA (aOR 0.93, 95%CI:0.54–1.60) was not significantly decreased. After matching patients through the propensity score, TA reduced significantly the risk of in-hospital mortality (OR 0.58, 95%CI:0.35–0.98; 3500 patients).

Conclusions: The whole cohort data does not support the routine use of TA in P-PCI, but the results of the propensity-score matched cohort suggests that the use of selective TA may improve the short-term risks of STEMI.

Keywords: Thrombectomy, Thrombus aspiration, Mortality, Portugal, Primary PCI, Angioplasty

Background

The impact of thrombus aspiration (TA) during primary percutaneous coronary intervention (P-PCI) has been widely discussed in the recent years. The removal of the thrombus before stent deployment has shown to improve myocardial blush grade [1], but evidence has been heterogeneous regarding pragmatic outcomes, namely mortality. Survival benefits were previously supported by the TAPAS trial [1], as well as subsequent meta-analyses [2], including of patient level meta-analysis [3]. Both European and American guidelines for the management of patients with ST-Elevation Myocardial Infarction (STEMI) recommended that routine TA should be considered, based on evidence of moderate robustness (Class IIa, level of evidence B) [4, 5]. However, the results of larger trials did not show significant improvements in the mortality. Moreover, the existing evidence does not exclude the possibility of TA benefit in high-risk patients or in selected cases.

We intended to assess the impact of TA outside of the randomized controlled trial setting, to evaluate whether

* Correspondence: helder@netcabo.pt
† Equal contributors
1 Serviço de Cardiologia, Hospital Garcia de Orta EPE, Avenida Prof. Torrado da Silva, 2801-951 Almada, Portugal
2 Centro Cardiovascular da Universidade de Lisboa (CCUL), CAML, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, Lisboa 1649-028, Portugal
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
the findings of randomized controlled trials (RCTs) are similar to those occurring in the ‘real-world’.

Methods

Data was retrieved from the Registo Nacional de Cardiologia de Intervenção (RNCI, Portuguese Registry on Interventional Cardiology) between January 2006 and December 2012 [6].

This is a continuous, prospective and observational registry, which includes all consecutive patients undergoing coronary angiography in multiple centers with interventional cardiology. Until December 2012 there were overall 58,434 procedures registered.

All included patients gave informed consent for the intervention and data collection for CNCDC (Centro Nacional de Coleccção de Dados em Cardiologia from the Portuguese Society of Cardiology; http://www.spc.pt/CNCDC/) and the registry procedures are in accordance with the rules of CNPD (Comissão Nacional de Protecção de Dados – National Committee of Data Protection; https://www.cnpd.pt/). The registry was approved by the Portuguese Society of Cardiology ethics committee and local ethics committees.

Inclusion criteria was P-PCI within less than 12 h of symptom in the context of persistent (> 30 min) ST-segment elevation or new left bundle branch block [7–9].

Exclusion criteria were facilitated and rescue PCI as well stable coronary disease and non-ST elevation acute coronary syndromes.

Patients were stratified in two groups per the presence or absence of TA in the index procedure. TA was performed at the discretion of the operator. Demographic, clinical, patient management-related characteristics, as well as clinical outcomes were assessed.

Our primary outcome was all-cause mortality during the index hospitalization.

The risk was determined by odds ratio (OR) and 95% confidence intervals (CIs) were calculated for the primary outcome. Differences between patients treated with both TA and P-PCI, and those with PCI-PCI alone were adjusted through multivariable regression analysis.

All demographic information, comorbidities and TIMI flow pre-PCI data were included in a multivariable logistic regression to estimate a propensity score for the likelihood of being treated with thrombus aspiration. Matching was performed in a 1:1 fashion using with a 0.05 calliper width of the propensity score [10].

The analyses were further adjusted to residual confounding through multivariable logistics regression, to derive adjusted OR and 95%CIs. Statistical analyses were performed with SPSS version 19.0 (SPSS Inc., Chicago, IL, USA).

Results

A total of 9458 procedures fulfilled the inclusion criteria and 35% of them had adjunctive thrombus aspiration.

Time trends show that this procedure had been increasing overtime (Fig. 1).

In the whole cohort, patients treated with TA were overall younger and had lower proportion of cardiovascular risk factors, with exception of smoking, as well as lower proportion of major comorbidities (Table 1). Patients in the group of TA had more frequently a left anterior descending artery occlusion. In the patients with TA the radial access was more common than other accesses, as well as stenting and use of GP IIb/IIIa inhibitors (Table 1).

The overall in-hospital mortality was non-significantly lower (2.2% vs 2.8%) in the TA group (Fig. 2). Differences between important baseline characteristics were adjusted to confounders and the estimate of TA impact on mortality remained non-significant (OR 0.93, 95%CI 0.54–1.60, \( p = 0.79 \)) (Fig. 2).

The stroke rate was low and thrombus aspiration was unlikely to affect its risk in our cohort (TA + P-PCI vs. P-PCI: 0.1% vs. 0.2%, \( p = 0.77 \)).

We conducted a sub-analysis among the 7,692 patients that full fielded the inclusion criteria and had full information about the TIMI flow of coronary arteries.
Table 1 Clinical characteristics of included patients according to the use of thrombus aspiration during P-PCI

|                          | Before Matching | After Matching | p-value |
|--------------------------|-----------------|----------------|---------|
|                          | Thrombus aspiration and P-PCI (n = 3311) | P-PCI only (n = 6247) | p-value |
| Age                      | 60 ± 13         | 63 ± 13        | < 0.001 | 61 ± 13         | 60 ± 13         | 0.10 |
| Male                     | 77.4%           | 74.6%          | 0.002   | 77.7%           | 78.6%           | 0.59 |
| Risk factors             |                 |                |         |                 |                |     |
| Dyslipidemia             | 44.7%           | 44.6%          | 0.95    | 45.0%           | 46.2%           | 0.50 |
| DM                       | 18.7%           | 24.0%          | < 0.001 | 19.0%           | 18.9%           | 0.93 |
| Smoking                  | 43.1%           | 36.4%          | < 0.001 | 41.8%           | 45.0%           | 0.38 |
| Hypertension             | 53.3%           | 59.7%          | < 0.001 | 54.1%           | 54.5%           | 0.87 |
| Previous history         |                 |                |         |                 |                |     |
| MI                       | 11.3%           | 14.2%          | < 0.001 | 12.1%           | 12.3%           | 0.84 |
| PCI                      | 12.3%           | 14.0%          | 0.035   | 12.9%           | 13.8%           | 0.46 |
| CABG                     | 1.3%            | 1.7%           | 0.188   | 1.3%            | 1.1%            | 0.64 |
| Stroke                   | 3.9%            | 5.2%           | 0.009   | 4.0%            | 4.1%            | 1.00 |
| PAD                      | 1.9%            | 3.1%           | 0.002   | 1.9%            | 1.9%            | 1.00 |
| HF                       | 0.9%            | 1.9%           | < 0.001 | 0.8%            | 0.6%            | 0.69 |
| CKD                      | 3.2%            | 3.4%           | 0.56    | 3.7%            | 4.6%            | 0.21 |
| Admission                |                 |                |         |                 |                |     |
| KK IV class              | 6.3%            | 6.6%           | 0.57    | 7.3%            | 6.4%            | 0.43 |
| Infarction-related artery|                 |                |         |                 |                |     |
| LM                       | 1.0%            | 1.3%           | 0.20    | 3.6%            | 3.5%            | 0.86 |
| LAD                      | 42.4%           | 35.7%          | < 0.001 | 69.1%           | 69.4%           | 0.86 |
| Circumflex               | 13.4%           | 17.5%          | < 0.001 | 39.5%           | 46.8%           | < 0.001 |
| RCA                      | 42.8%           | 45.1%          | 0.03    | 58.8%           | 57.3%           | 0.36 |
| Radial access            | 40.2%           | 22.9%          | < 0.001 | 40.3%           | 20.3%           | < 0.001 |
| Stenting / DES           | 79.4% / 47.5%   | 75.9% / 50.9%  | < 0.001 | 91.6% / 45.4%   | 90.9% / 46.9%   | 0.50 / 0.40 |
| GpIIb/IIia               | 36.9%           | 18.9%          | < 0.001 | 51.9%           | 31.0%           | < 0.001 |

CABG: Coronary artery bypass graft, CKD: Chronic kidney disease, DES: Drug-eluting stent, DM: Diabetes Mellitus, HF: heart failure, KK: Killip-Kimball, LAD: Left Anterior Descending Artery, LM: Left Main Artery, MI: Myocardial infarction, PAD: peripheral artery disease, PCI: angioplasty/percutaneous coronary intervention, P-PCI: Primary angioplasty. RCA: Right Coronary Artery, TA: Thrombus aspiration.

Fig. 2 Risk of in-hospital mortality with thrombus aspiration in the whole cohort and in the propensity score matched cohort.
Patients with TA had more frequently post-PCI TIMI flow<3 compared to those without TA (14.0% vs.10.6%).

After propensity score matching, 1750 patients remained in each group. The details of patients’ characteristics are depicted in Table 1. The risk of in-hospital mortality was significantly increased (OR 0.65, 95%CI 0.43–0.97, \( p = 0.03 \)), and remained after the multivariable logistic regression (OR 0.58, 95%CI 0.35–0.98, \( p = 0.04 \)) (Fig. 2).

Discussion

This data based on a large real-world prospective registry, showed that TA decreased the risk of mortality among patients with STEMI that underwent P-PCI after matching the patients’ characteristics for the likelihood of being treated with TA. In Portugal we observed an increase in the use of TA but more than 50% of P-PCI evaluated were performed without this technique. It is possible that in some case TA was used as a bail-out procedure because the use of inhibitors of GpIIbIIIa was higher in the TA group. Our results are distinct from those obtained in largest RCTs, the TASTE and TOTAL trials [11, 12]. Despite the matching and the multivariable adjustments, our data is still retrospective, underpowered and with possible residual confounding bias.

Improving the microvascular perfusion in patients with STEMI is attractive, particularly when large macroscopic thrombi are retrieved. It provides the feeling that operators interfere directly with the pathophysiologic mechanics and improve the prognostic of patients. The RCT data show that routine thrombus aspiration does not seem to influence the mortality of patients with STEMI. However, our data suggests that ‘selective’ TA may be useful to improve outcomes in patients with STEMI. The recognition of the type of patients in which TA is likely to be successful may be the key to the obtained results.

Due to limited data accuracy for other outcomes, our study only covered the in-hospital mortality. Similarly to the results regarding the short-term outcomes, the major trials also showed that TA did not improve 1-year outcomes [13, 14]. The results of observational data are heterogeneous. In a cohort with more than 10,000 patients with STEMI (about 3500 of STEMI patients treated with TA and P-PCI), TA did not show improvement in the risk of mortality [15]. Inversely, other observational studies showed that a ‘selective’ TA in P-PCI can improve outcomes, mortality included [16, 17]. The best available evidence, based on RCTs, is robust for not using ‘routinely’ the TA in P-PCI but do not preclude the use of TA in selected cases, as occurs with other interventions available for acute cardiac care setting [18].

In this cohort the rates of stroke were very low, and no differences were found between the groups, despite the cumulative evidence regarding this adverse event which is known to have a small increase in the absolute risk with TA [19].

Limitations

Our results are limited because this is a consecutive all-comers procedural registry that has inherently limitations due to the lack of randomization and blinding effect. Despite the adjustment to multiple clinical and angiographic characteristics, it is worth noting that the data may not adjust to all potential confounders and thus increase the risk of bias in the analyses. The propensity score matching partially improves some of these limitations. However, this matching occurs with a decrease of the sample size which increases the risk of type II errors [20, 21]. Unfortunately, there are no data regarding the types of devices used in the TA as well as additional details of operators and procedures, which also hampers the conclusions.

Conclusion

The use of thrombus aspiration did not have a significant impact in the short-term prognosis of STEMI patients that underwent primary percutaneous coronary intervention in the whole cohort. The results of the propensity-score matched cohort suggests a potential role for selective thrombus aspiration.

Abbreviations

95%CI: 95% confidence interval; CNCDC: Centro nacional de coleção de dados em cardiologia; CNPD: Comissão nacional de protecção de dados – national committee of data protection; GpIIbIIIa: Glycoproteins IIb/IIIa; OR: Odds ratio; P-PCI: Primary percutaneous coronary intervention; RCT: Randomized controlled trials; RNCI: Registo nacional de cardiologia de intervenção - portuguese registry on interventional cardiology; STEMI: ST-elevation myocardial infarction; TA: Thrombus aspiration; TASTE: Thrombus aspiration in myocardial infarction; TOTAL: A trial of routine aspiration thrombectomy with Percutaneous Coronary Intervention (PCI) versus PCI alone in patients with ST-Segment Elevation Myocardial Infarction (STEMI) Undergoing Primary PCI

Acknowledgments

We would like to acknowledge Dra. Adriana Belo for performing the statistical analyses presented in this manuscript.

Funding

None.

Availability of data and materials

The data is held by Centro Nacional de Coleção de Dados em Cardiologia (CNCDC) (http://www.spc.pt/CNCDC/). The data is not publicly available and Dr. Hélder Pereira (helder@netcabo.pt) can be contacted in order to request permission to view the data for non-commercial purposes.

Authors’ contributions

HP and DC: Contributed to the concept and design, data acquisition, data analysis, and interpretation of the data; wrote the first draft of the manuscript; critically revised the manuscript; and gave final approval of the submitted manuscript; RCT, MC, PCS, VGR, VB, DM, FM, FPM, JB, PFA, RC, AD, HCC, JC, JCS, ILP, JM, PS, RF, RCF, SR, EIO, MA: contributed to the data analysis and interpretation; critically revised the manuscript; and gave final approval of the submitted manuscript.
Ethics approval and consent to participate
All included patients gave informed consent for the intervention and data collection for CNDC (Centro Nacional de Coleção de Dados em Cardiologia from the Portuguese Society of Cardiology; http://www.spc.pt/CNDC/) and the registry procedures are in accordance with the rules of CNPO (Comissão Nacional de Protecção de Dados – National Committee of Data Protection; https://www.cnpd.pt/). The registry was approved by the from the Portuguese Society of Cardiology ethics committee. Protection of human subjects: The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki). Confidentiality of data: The authors declare that they have followed the protocols of their work center on the publication of patient data.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Serviço de Cardiologia, Hospital Garcia de Orta EPE, Avenida Prof. Torrado da Silva, (2801-951) Almada, Portugal. 2Centro Cardiovascular da Universidade de Lisboa (CCUL), CAML, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, Lisboa 1649-028, Portugal. 3Unidade de Farmacologia Clínica, Instituto de Medicina Molecular; Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, Lisboa 1649-028, Portugal. 4Hospital de Santa Cruz, Centro Hospitalar de Lisboa Ocidental, EPE, Lisboa, Portugal. 5Hospital de Santa Maria, Centro Hospitalar de Lisboa Norte EPE, Lisboa, Portugal. 6Hospital de Santa Casa de Misericórdia de Lisboa, Centro Hospitalar de Lisboa Norte EPE, Lisboa, Portugal. 7Hospital de Santa Maria, Centro Hospitalar de Lisboa Norte EPE, Lisboa, Portugal. 8Hospital hospitalar e Universitário de Coimbra – CHC, Coimbra, Portugal. 9Hospital de Santa Maria, Centro Hospitalar de Lisboa Norte EPE, Lisboa, Portugal. 10Hospital de Pombal, Centro Hospitalar de Lisboa Norte EPE, Lisboa, Portugal. 11Hospital de São Bernardo, Centro Hospitalar de Setúbal EPE, Setúbal, Portugal. 12Hospital da Luz, Lisboa, Portugal. 13Hospital de São Vicente de Fora, Centro Hospitalar de Lisboa Norte EPE, Lisboa, Portugal. 14Centro Hospitalar e Universitário de Coimbra – HUC, Coimbra, Portugal. 15Hospital de Florestal, Madeira, Portugal. 16Hospital de Santo António, Centro Hospitalar do Porto, Porto, Portugal. 17Hospital de São Teotónio, Porto, Portugal. 18Hospital de São Marcos, Braga, Portugal. 19Hospital de Vila Real, Centro Hospitalar de Trás-os-Montes e Alto Douro EPE, Vila Real, Portugal. 20Hospital do Espírito Santo, Ovar, Portugal. 21Hospital de Santa Marta, Centro Hospitalar Lisboa Central EPE, Lisboa, Portugal. 22Hospital CUF Infante Santo, Lisboa, Portugal. 23Hospital de Santa Cruz, CHCO, Departamento de Fisiopatologia Nova Medical School, Lisboa, Portugal.

Received: 7 November 2017 Accepted: 20 March 2018
Published online: 24 April 2018

References
1. Silva T, Vilar PI, van der Horst IC, Drieks GF, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suermeijer AJ, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008;358(6):575–67.
2. Kumbhani DJ, Bavry AA, Desai MY, Bangalore S, Bhatt DL. Role of aspiration and mechanical thrombectomy in patients with acute myocardial infarction undergoing primary angioplasty: an updated meta-analysis of randomized trials. J Am Coll Cardiol. 2013;62(14):1409–18.
3. Buzzotta F, De Vita M, Gu YL, Ishiki T, Lefever T, Kaltoft A, Dudek D, Sandella G, Orrego PS, Antoniucci D, et al. Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials. Eur Heart J. 2009;30(18):2193–203.
4. Steg PG, James SK, Atar D, Badano LP, Böhm M, Cooil B, Dickstein K, Duroq G, Fernandez-Avalos F, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569–9.
5. O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, De Lemos JA, Ettinger SM, Faxon DC, Fesmire FM, Franklin BA. 2013 AACE/aha guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;61(4):e78-e140.
6. Cale R, de Sousa L, Pereira H, Costa M, de Sousa Almeida M, Primary angioplasty in women: data from the Portuguese registry of interventional cardiology. Rev Port Cardiol. 2014;33(6):535–61.
7. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J. 2012;33(20):2551–67.
8. Mendis S, Thygesen K, Kaukamsa K, Giampaoli S, Mahonen M, Ngublack K, Lisheng L. World Health Organization definition of myocardial infarction: 2008–2009 revision. Int J Epidemiol. 2011;40(1):139–46.
9. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol. 2007;50(22):2173–95.
10. Portugal G, Cunha P, Valente B, Feliciano J, Louissina A, Alves S, Brao M, Pimenta R, Delgado AS, Oliveira M, et al. A link to better care: the effect of remote monitoring on long-term adverse cardiac events in a propensity-scoring matched cohort. Rev Port Cardiol. 2017;36(3):189–95.
11. Frobert O, Lagerqvist B, Oliveira G, Omverson E, Gudnason T, Maeng M, Aasa M, Angares O, Calais F, Danielewicz M, et al. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med. 2013;369(17):1587–97.
12. Jolly SS, Cairns JA, Yusuf S, Meeks B, Pogue J, Rokoss MJ, Kedev S, Thabane L, Stankovic G, Moreno R, et al. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med. 2015;372(15):1389–98.
13. Lagerqvist B, Frobert O, Oliveira G, Gudnason T, Maeng M, Alstrom P, Andersson J, Calais F, Carlsson J, Colliste O, et al. Outcomes 1 year after thrombus aspiration for myocardial infarction. N Engl J Med. 2014;371(12):1111–20.
14. Jolly SS, Cairns JA, Yusuf S, Rokoss MJ, Gao P, Meeks B, Kedev S, Stankovic G, Moreno R, Gershlick A, et al. Outcomes after thrombus aspiration for ST-elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. Lancet. 2016;387(10014):127–35.
15. Jones DA, Rathod KS, Gallagher S, Jain AK, Kalra SS, Lim P, Crake T, Ozkor M, Rakith R, Knight CJ, et al. Manual Thrombus aspiration is not associated with reduced mortality in patients treated with primary percutaneous coronary intervention: an observational study of 10,929 patients with ST-segment elevation myocardial infarction from the London heart attack group. JACC Cardiovasc Interv. 2015;8(4):575–84.
16. Javid A, Siddiqi NH, Steinberg DH, Buch AN, Sottow TL, Roy P, Sammee S, Okabe T, Suddath WO, Kant KW, et al. Adjunct thrombus aspiration reduces mortality in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction with high-risk angiographic characteristics. Am J Cardiol. 2008;101(4):452–6.
17. Shiraishi J, Kohno Y, Nakamura T, Yaguchi T, Hashimoto S, Tada O, Ikimura M, Matiui A, Yoko H, Arihara M, et al. Clinical impact of thrombus aspiration during primary percutaneous coronary intervention in acute myocardial infarction with occluded culprit. Cardiovasc Interv Ther. 2015;30(1):22–8.
18. Caldeira D, Pereira H, Costa J, Vaz-Camacho A, Cochrane corner: intra-aortic balloon pump in patients with cardiogenic shock following myocardial infarction. Rev Port Cardiol. 2016;35(4):229–31.
19. Barkghan M, Steinfl A, Berchenko Y, Finkelstein A, Kerem G, Banai S, Halkin A. Impact of routine manual aspiration thrombectomy on outcomes of patients undergoing primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis. Int J Cardiol. 2016;204(189–95.
20. Akobeng AK. Understanding type I and type II errors, statistical power and sample size. Acta Paediatr. 2016;105(5):665–9.
21. Camacho AV. Estimating sample size in clinical studies: basic methodological principles. Rev Port Cardiol. 2003;22(12):1513–21.